Clinical Trial Update: HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC

View source ↗

Summary

A trial is evaluating hepatic arterial infusion chemotherapy (HAIC) in combination with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• Hepatic arterial infusion chemotherapy (HAIC) (hepatic arterial infusion chemotherapy)

Snippet

Sponsor: RenJi Hospital | Conditions: Unresectable Hepatocellular Carcinoma | Status: NOT_YET_RECRUITING